News
PDSB
2.645
-8.79%
-0.255
Weekly Report: what happened at PDSB last week (0408-0412)?
Weekly Report · 5d ago
Weekly Report: what happened at PDSB last week (0401-0405)?
Weekly Report · 04/08 10:13
Weekly Report: what happened at PDSB last week (0325-0329)?
Weekly Report · 04/01 10:12
PDS Biotechnology Price Target Cut to $11.00/Share From $14.00 by B. Riley Securities
Dow Jones · 03/28 16:10
B. Riley Securities Reiterates Buy on PDS Biotechnology, Lowers Price Target to $11
Benzinga · 03/28 16:00
Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)
Robert LeBoyer from Noble Financial maintained a Buy rating on PDS Biotechnology (PDSB) with a price target of $17.00. The company’s shares closed yesterday at $3.85. The stock has an analyst consensus of Strong Buy and a 324.16% upside from current levels.
TipRanks · 03/28 12:25
PDS Biotechnology: Strategic Shift to Triplet Therapy Promises Enhanced Clinical Success
TipRanks · 03/28 11:25
12 Health Care Stocks Moving In Wednesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) shares increased by 46.1% to $15.03 during Wednesday's regular session. The company's market cap stands at $671.1 million. Nutriband stock rose 24.33% as the company's Q4 earnings came out yesterday. Lixte Biotechnology and Ontrak also moved upwards.
Benzinga · 03/27 16:31
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023
PDS Biotechnology reported earnings per share of -35 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -44 cents. PDS Biotech was down 2% after the close of trading on Thursday afternoon.
Investorplace · 03/27 15:52
PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/27 14:39
PDS Biotechnology: A Strong Buy on Strategic Focus and Promising HNSCC Trial Data
TipRanks · 03/27 14:35
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Maintains $21 Price Target
Benzinga · 03/27 14:28
PDS Biotechnology Corp reports results for the quarter ended in December - Earnings Summary
PDS Biotechnology Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 35 cents per share. The mean expectation of seven analysts was for a loss of 44 cents. Reported revenue was zero; analysts expected zero; shares fell by 9.9% this quarter.
Reuters · 03/27 13:31
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Lixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The company's, Q4 earnings came out today. NovoCure stock rose 17.9% and Nutriband shares rose 24.34% in the same session. Akili stock decreased by 20.6% and OpGen stock fell 15.67% during the session.
Benzinga · 03/27 13:05
Options Volatility and Implied Earnings Moves Today, March 27, 2024
TipRanks · 03/27 12:05
PDS Biotechnology GAAP EPS of -$1.39 beats by $0.06
Seeking Alpha · 03/27 11:31
*PDS Biotechnology 2023 Research and Development Expenses $27.8M >PDSB
Dow Jones · 03/27 11:31
Press Release: PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results. Company to focus late-stage clinical strategy on triple combination of PDS01ADC and Versamune(R) HPV in advanced head and neck cancer. Unique mechanism of action of the combination results in 3-year survival of 75% and 75% overall response rate in advanced cancer trial. Company also reported its financial results for the year ended December 31, 2023.
Dow Jones · 03/27 11:30
*PDS Biotechnology 2023 Loss/Shr $1.39 >PDSB
Dow Jones · 03/27 11:30
Press Release: PDS Biotech Announces Clinical -2-
Our Infectimune(R) based vaccines have demonstrated the potential to induce powerful T-cell responses in pre-clinical studies. PDS Biotechnology Corporation is a subsidiary of Merck & Co., Inc. The company's forward-looking statements are based on current beliefs and are not guarantees of future performance.
Dow Jones · 03/27 11:30
More
Webull provides a variety of real-time PDSB stock news. You can receive the latest news about Pds Biotechnology Corporation through multiple platforms. This information may help you make smarter investment decisions.
About PDSB
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.